Financial Performance - Net profit attributable to shareholders increased by 134.01% to CNY 119,898,724.80 compared to the same period last year[6] - Operating revenue rose by 73.26% to CNY 947,611,114.24 compared to the same period last year[6] - Basic earnings per share increased by 85.71% to CNY 0.26 compared to the same period last year[6] - The weighted average return on equity increased by 0.96 percentage points to 3.17% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses increased by 155.96% to CNY 115,132,067.21 compared to the same period last year[6] - Operating profit for Q1 2018 was ¥144,292,740.13, up 118.5% from ¥65,960,758.70 in Q1 2017[20] - Net profit attributable to shareholders of the parent company was ¥119,898,724.80, representing a 133.5% increase from ¥51,236,792.95 in the previous year[21] - The company’s total comprehensive income for Q1 2018 was CNY 111,566,565.37, compared to CNY 56,076,103.48 in the same period last year, indicating a growth of 99.0%[23] Assets and Liabilities - Total assets increased by 3.58% to CNY 4,911,848,257.39 compared to the end of the previous year[6] - The company's total liabilities as of March 31, 2018, were RMB 1,060,069,203.09, compared to RMB 1,017,593,093.47 at the beginning of the year[15] - Total current assets increased to ¥3,316,283,399.97 from ¥3,138,113,537.74, reflecting a growth of 5.7%[17] - Total liabilities rose to ¥881,136,342.25, up from ¥842,628,343.45, indicating a 4.6% increase[18] - Total assets reached ¥4,743,560,790.52, an increase of 3.3% from ¥4,593,486,226.35 at the beginning of the year[17] - Total non-current assets decreased slightly to ¥1,427,277,390.55 from ¥1,455,372,688.61, a decline of 1.9%[17] Cash Flow - Net cash flow from operating activities decreased by 29.97% to CNY 82,871,837.14 compared to the same period last year[6] - The net cash flow from operating activities was CNY 82,871,837.14, down from CNY 118,339,074.50 in Q1 2017, showing a decrease of 30.0%[26] - Cash inflow from operating activities was CNY 722,436,158.90, up from CNY 446,232,436.78 in the previous year, reflecting a growth of 62.0%[25] - The company reported a net cash outflow from investing activities of CNY 1,075,377,153.17, compared to a minimal outflow of CNY 77,048.46 in the previous year[27] - Cash and cash equivalents at the end of the period totaled CNY 396,237,733.78, down from CNY 272,686,602.11 at the end of Q1 2017[27] - The company incurred CNY 639,564,321.76 in cash outflows from operating activities, which is an increase from CNY 327,893,362.28 in Q1 2017, reflecting a rise of 95.0%[26] Shareholder Information - The total number of shareholders reached 38,328 at the end of the reporting period[8] - The top shareholder, Chenxin Technology Group Co., Ltd., holds 36.54% of the shares[8] Expenses - The company's sales expenses rose by 117.73%, totaling RMB 302,498,852.25, driven by increased market development costs[9] - The financial expenses decreased by 77.12%, amounting to RMB 121,207.49, due to reduced loan interest and increased deposit income[9] - The company's management expenses increased by 52.34%, reaching RMB 71,445,268.78, primarily due to higher R&D expenses[9] Government Support - The company received government subsidies amounting to CNY 5,041,572.30 during the reporting period[6] Other Financial Metrics - The company's cash and cash equivalents decreased by 71.02%, from RMB 1,403,402,729.84 to RMB 406,762,058.59, due to the investment of temporarily idle funds[9] - Other receivables increased by 413.54%, reaching RMB 38,389,723.02 compared to RMB 7,475,490.47 in the previous year, attributed to increased rent and loans[9] - Total operating costs for Q1 2018 were ¥817,085,649.51, up 67.6% from ¥487,107,629.76 in the previous year[20] - The company reported an investment income of ¥8,436,575.71, compared to a loss of ¥985,760.90 in the same period last year[20]
辰欣药业(603367) - 2018 Q1 - 季度财报